Welcome to InfiCure Bio
InfiCure Bio is a life science company focusing on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions.
Based on a panel of in vivo models for these conditions including a proprietary model, the NIF mouse, for chronic inflammation and fibrosis, we offer effect tests of anti-inflammatory and anti-fibrotic drugs.
Founded on extensive experience and expertise in immunology, inflammation and fibrosis research, InfiCure Bio offers a proficient and flexible processing of drug validation projects in this area.
News
Pressrelease published on the CymaBay Seladelpar study!
Take the opportunity to read the pressrelease on the CymaBay study with Seladelpar in the NIF mouse. Ed Cable, sr. Director of Research at CymaBay Therapeutics, gives his view on why CymaBay chose to work [...]
Check out CymaBay Therapeutics poster on the NIF mouse at AASLD!
We are very happy that CymaBay Therapeutics chose to present the convincing data from their study in the NIF mouse. They nicely show that Seladelpar, which is a substance in clinical studies, reduces fibrosis in [...]
The NIF mouse in Cyma Bay preclinical study using Seladelpar
We are happy and proud that our NIF mouse is the model used in the preclinical poster presented by Cymabay Therapeutics at the upcoming AASLD meeting, with the title "Seladelpar reduces established liver and renal [...]
Take a look at InfiCures poster from the EASL NAFLD Summit!
InfiCure Bio attended the EASL NAFLD Summit in September, and presented this poster with up-to-date data on the NIF mouse.